Your browser doesn't support javascript.
loading
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
Belkouz, A; Wilmink, J W; Haj Mohammad, N; Hagendoorn, J; de Vos-Geelen, J; Dejong, C H C; Homs, M Y V; Groot Koerkamp, B; van Gulik, T M; van Oijen, M G H; Punt, C J A; Klümpen, H.
Afiliación
  • Belkouz A; Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Wilmink JW; Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Haj Mohammad N; UMC Utrecht Cancer Center/RAKU, Dept. of Medical Oncology, Utrecht University, Utrecht, the Netherlands.
  • Hagendoorn J; UMC Utrecht Cancer Center/RAKU, Dept. of Surgery, Utrecht University, Utrecht the Netherlands.
  • de Vos-Geelen J; Maastricht UMC+, GROW - School for Oncology and Developmental Biology, Dept. Internal Medicine, Div. of of Medical Oncology, Maastricht, the Netherlands.
  • Dejong CHC; Department of Surgery and School of Nutrition and Translational Research in Metabolism, Maastricht UMC+, Maastricht, the Netherlands and Department of Surgery, Universitätsklinikum Aachen, Aachen, Germany.
  • Homs MYV; Erasmus MC, Dept. of Medical Oncology, Rotterdam, the Netherlands.
  • Groot Koerkamp B; Erasmus MC, Dept. of Surgery Rotterdam, the Netherlands.
  • van Gulik TM; Amsterdam UMC, Dept. of Surgery, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van Oijen MGH; Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Punt CJA; Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Klümpen H; Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: h.klumpen@amsterdamumc.nl.
Crit Rev Oncol Hematol ; 151: 102975, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32464483
ABSTRACT
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Quimioterapia Adyuvante / Ensayos Clínicos Fase III como Asunto / Ensayos Clínicos Fase II como Asunto / Capecitabina / Antimetabolitos Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Quimioterapia Adyuvante / Ensayos Clínicos Fase III como Asunto / Ensayos Clínicos Fase II como Asunto / Capecitabina / Antimetabolitos Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos